Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope

Regeneron Pharmaceuticals

13/04/2026 03:38

** Telix Pharmaceuticals TLX.AX rises as much as 8.8% to A$15.93, highest since November 5, 2025

** Stock logs biggest intraday pct gain since March 10

** Biopharma major and biotech co Regeneron Pharmaceuticals REGN.O announce collaboration to jointly develop, commercialise radiopharmaceutical therapies

** Telix says it will receive $40 mln from Regeneron, potentially earn up to $2.1 bln in payments, royalties

** Citi says collaboration looks potentially "broad" in scope; adds partnership may not be limited to radiation studies

** Stock rated "buy" on avg; median PT is A$23.15, per data compiled by LSEG

** YTD, TLX up 38.8%

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))